Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group

Naghmeh Niktoreh; Beate Lerius; Martin Zimmermann; Bernd Gruhn; Gabriele Escherich; Jean-Pierre Bourquin; Michael Dworzak; Lucie Sramkova; Claudia Rossig; Ursula Creutzig; Dirk Reinhardt; Mareike Rasche

doi:10.3324/haematol.2018.191841

Haematologica (Jan 2019)

Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group

Naghmeh Niktoreh,
Beate Lerius,
Martin Zimmermann,
Bernd Gruhn,
Gabriele Escherich,
Jean-Pierre Bourquin,
Michael Dworzak,
Lucie Sramkova,
Claudia Rossig,
Ursula Creutzig,
Dirk Reinhardt,
Mareike Rasche

Affiliations

Naghmeh Niktoreh: Department of Pediatric Hematology and Oncology, University Hospital Essen, Germany
Beate Lerius: Department of Pediatric Hematology and Oncology, University Hospital Essen, Germany
Martin Zimmermann: Department of Pediatric Hematology and Oncology, Hannover Medical School, Germany
Bernd Gruhn: Department of Pediatrics, Jena University Hospital, Germany
Gabriele Escherich: Department of Pediatric Hematology and Oncology, Eppendorf University Hospital, Hamburg, Germany
Jean-Pierre Bourquin: Division of Pediatric Hematology/Oncology, University Children’s Hospital Zurich, Switzerland
Michael Dworzak: St. Anna Children’s Hospital and Children’s Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Austria
Lucie Sramkova: Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Claudia Rossig: University Children’s Hospital Münster, Pediatric Hematology and Oncology, Germany
Ursula Creutzig: Department of Pediatric Hematology and Oncology, Hannover Medical School, Germany
Dirk Reinhardt: Department of Pediatric Hematology and Oncology, University Hospital Essen, Germany
Mareike Rasche: Department of Pediatric Hematology and Oncology, University Hospital Essen, Germany

DOI: https://doi.org/10.3324/haematol.2018.191841
Journal volume & issue: Vol. 104, no. 1

Abstract

Read online

Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We evaluated gemtuzumab ozogamicin (CD33-targeted drug) used on a compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia Berlin-Frankfurt-Münster studies, and identified 76 patients (

Published in Haematologica

ISSN: 0390-6078 (Print); 1592-8721 (Online)
Publisher: Ferrata Storti Foundation
Country of publisher: Italy
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
Website: http://www.haematologica.org

About the journal